• Source
    • "Animal models also provided further indirect support for the role of glutamate dysfunction in OCD: particularly, the DLGAP3 and Sltrk5 knockout mouse models display remarkably similar phenotypes of compulsive grooming behavior associated with glutamate signaling dysfunction [27]. Finally, open label studies and case reports suggest that glutamatergic agents, such as riluzole [16], memantine [21] and N-acetylcysteine[11], might have therapeutic effects in OCD. More recently, a glutamate transporter gene, SLC1A1, has been proposed to be involved in OCD in particular because it is a chromosome 9p24 positional candidate gene from linkage analyses [8] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Different genetic polymorphisms in the SLC1A1 have been shown to be associated with obsessive-compulsive disorder. Rs301430 is a T/C functional polymorphism affecting the gene expression and extrasynaptic glutamate concentration.We observed that Rs301430 influence age at onset in obsessive-compulsive disorder.
    European Psychiatry 04/2014; DOI:10.1016/j.eurpsy.2014.02.006 · 3.21 Impact Factor
  • Source
    • "Animal models also provided further indirect support for the role of glutamate dysfunction in OCD: particularly, the DLGAP3 and Sltrk5 knockout mouse models display remarkably similar phenotypes of compulsive grooming behavior associated with glutamate signaling dysfunction [27]. Finally, open label studies and case reports suggest that glutamatergic agents, such as riluzole [16], memantine [21] and N-acetylcysteine[11], might have therapeutic effects in OCD. More recently, a glutamate transporter gene, SLC1A1, has been proposed to be involved in OCD in particular because it is a chromosome 9p24 positional candidate gene from linkage analyses [8] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Different genetic polymorphisms in the SLC1A1 have been shown to be associated with obsessive-compulsive disorder. Rs301430 is a T/C functional polymorphism affecting the gene expression and extrasynaptic glutamate concentration.We observed that Rs301430 influence age at onset in obsessive-compulsive disorder.
  • Source
    • "Because of its antiglutamatergic effect and its relative safe profile, riluzole has been used in a number of trials for psychiatric conditions in which glutamate excess has been proposed as part of the pathologic mechanism. There have been seven open-label trials of riluzole (three of them using riluzole as monotherapy) in adult subjects: Three in major depressive disorder (MDD) (Zarate et al. 2004; Sanacora et al. 2007; Mathew et al. 2010), one in bipolar depression (Zarate et al. 2005), one in generalized anxiety disorder (GAD) (Mathew et al. 2005), and two in the treatment of OCD (Coric et al. 2005; Pittenger et al. 2008a). There has been only a single reported study in children, a small open-label trial in childhood OCD in which riluzole was added to other medications (Grant et al. 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The antiglutamatergic drug riluzole (Rilutek) is presently being used off label in the treatment of psychiatric conditions in adult patients and, increasingly, in children. This article briefly reviews the pharmacology of this drug and its current investigative and clinical uses and adverse effects. It also reports on our experience to date in the study of the drug in children, with emphasis on adverse effects noted so far in these younger patients.
    Journal of child and adolescent psychopharmacology 08/2010; 20(4):309-15. DOI:10.1089/cap.2010.0009 · 3.07 Impact Factor
Show more